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Reinventing Primaquine for Endemic Malaria
JK Baird
Eijkman-Oxford Clinical Research Unit, Jalan Diponegoro No.69, Jakarta 10430, Indonesia
Abstract
After sixty years of continuous use, primaquine remains the only therapy licensed for arresting
transmission and relapse of malaria. The US Army developed primaquine for soldiers in a wartime
crisis setting. The dosing strategies suited to that narrow population were adopted without
modification or validation for the broader population of humans exposed to risk of malaria. The
poor suitability of these strategies in populations exhibiting greater vulnerability to hemolytic
toxicity among glucose-6-phosphate dehydrogenase deficient patients has not been addressed.
Primaquine requires chemotherapeutic reinvention delivering less threatening doses by leveraging
unexplored co-drug synergies.
Keywords
Primaquine; G6PD deficiency; hemolytic toxicity; malaria elimination
New Tools for New Strategy
Malaria remains a threat to several billion people exposed to risk in endemic zones. Global
strategy for coping with this threat aimed for minimizing the burden of disease through
indefinitely sustainable interventions. A few years ago, however, the World Health
Organization (WHO) formally endorsed calls for adopting strategy for malaria elimination.
Interventions could no longer count sustained low-level transmission of malaria as a success
– cessation of transmission now stands as the benchmark of success against endemic
malaria. This new strategic thinking sparked understanding of the inadequacy of available
chemotherapeutics tools and strategies in coping with diverse populations of parasites
deeply embedded within the human and mosquito populations in endemic zones. Obsession
with treatment of the acute attack attended neglect of chemotherapeutic attack of the many
silent forms of malaria – most out of diagnostic reach and thus not challenged by
conventional approaches to malaria chemotherapy [1]. Eliminating malaria will likely
require a profound shift in chemotherapeutics strategic thinking that brings treatments to
bear against the silent malarias that dominate endemic zones.
Consideration of the development and use of the 8-aminoquinoline drug primaquine
demonstrates the conspicuous neglect of the silent malarias as a chemotherapeutics problem,
and points to likely avenues of work that solve the problem. Modern antimalarials emerged
from drug discovery programs aimed principally at soldiers at war. In describing the
wartime efforts of the US government in antimalarial drug development during the 1940s,
Shannon [2] wrote, “The primary purpose of the investigations has been, at all times, to
+62 21 391 0414: +62 21 3190 5016: kbaird@eocru.org.
Declaration of interest: JKB receives research funding from the Medicines for Malaria Venture and serves as an unpaid member of
an advisory board to GSK on the development of tafenoquine. He serves as a consultant and advisor to WHO on issues pertaining to
primaquine therapy.
Europe PMC Funders Group
Author Manuscript
Expert Opin Emerg Drugs. Author manuscript; available in PMC 2012 December 04.
Published in final edited form as:
Expert Opin Emerg Drugs. 2012 December ; 17(4): 439–444. doi:10.1517/14728214.2012.720252.
 Europe PM
C Funders A
uthor M
anuscripts
 Europe PM
C Funders A
uthor M
anuscripts
satisfy the specific needs of the armed services.” This perspective dominated antimalarial
drug development through the remainder of the 20th century. Newer antimalarials like
mefloquine and the artemisinins derived from the strategic needs of two military camps
pitted against one another in the war in Vietnam: the US Army and the Army of the People’s
Republic of China [3]. Creation of the Medicines for Malaria Venture in the 1990s, a public-
private consortium committed to development of drugs relevant to residents of endemic
zones, acknowledged the poor suitability of therapeutics intended for soldiers and travelers.
A Military Drug
Primaquine derived from military strategic urgency. The onset of war in the Pacific denied
Allied forces access to quinine against acute malaria – 95% of that global supply came from
plantations in Java firmly in the hands of the Imperial Japanese armed forces in 1942. The
Allies mobilized the production of atabrine, an inferior synthetic antimalarial for prevention
and treatment. The predecessor of primaquine, pamaquine, was withdrawn for therapy
against relapse of P. vivax in 1943 because atabrine exacerbated its already notorious
toxicity [4]. The United States government feared not only the threat that relapse posed to
victory in the Pacific, but also reintroduction of the then vanishing endemic vivax malaria by
returning servicemen harboring latent tissue stages [1]. Despite this urgency, improving
upon pamaquine required 8 years of effort.
That effort naturally focused upon the specific requirements of the US Army. After
discovery of glucose-6-phosphate dehydrogenase deficiency (G6PDd) as the basis of
hemolytic sensitivity to 8-aminoquinolines in 1956 [5], the Army sought regimens of
therapy not threatening the most vulnerable troops, principally African-Americans having
the A-variant of G6PDd. That variant exhibits mild and self-limiting hemolytic sensitivity to
primaquine [6], whereas other variants, like Mediterranean B-, pose far greater risk of
threatening complications following primaquine therapy [7].
The safety of the primaquine regimens the Army wished to apply were evaluated in healthy
adult volunteers with A-G6PDd, and very few of them [8]. The Army used 15mg
primaquine daily for 14 days when G6PDd status was not known, or 45mg weekly for 8
weeks in G6PDd patients. The prolonged dosing of 14 days mitigated risk to unscreened
G6PDd patients, and the 8 weeks of weekly dosing seemed safe and effective in A-G6PDd
patients [6]. Further, the US Army determined that the 45mg weekly primaquine already in
use for chemoprophylaxis (along with 300mg chloroquine in the same tablet) [9] also killed
gametocytes of P. falciparum [10]. By the 1960s the US Army had its practical
chemotherapeutic solutions against hypnozoites and gametocytes (Table 1). The WHO, at
that time heavily reliant upon military expertise with antimalarials, readily adopted these
treatment strategies for global use [11].
An Incompletely Developed Drug
Therapies aimed at clinically silent forms like hypnozoites and gametocytes vanished from
the malaria chemotherapy research and development agenda. The inadequacy of primaquine
to chemotherapeutics in endemic zones escaped attention against a backdrop of global
strategy uncommitted to elimination/eradication. The perceived success of sustained low-
level transmission likely underpins the failure to acknowledge the importance of
chemotherapeutic attack of the silent malarias. The risks imposed by primaquine to
unscreened G6PDd patients abetted the neglect of its broad application against parasite
populations considered relatively non-threatening to patients and strategic aims.
The hasty development of primaquine failed to consider dose- and toxicity-minimizing
strategies in broader populations than American soldiers. The US Army primaquine
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regimens met their requirements and further development ceased around 1965. It is
important to acknowledge that those treatment strategies were never adapted, much less
optimized, to use in resource-limited settings presenting a diversity of G6PDd variants and
patients far beyond the US Army experience. Administration of primaquine causing severe
and fatal events indeed occurs [12-15], and providers in endemic zones are rationally
reluctant to apply regimens of unknown safety. The broad lack of contemporary evidence
demonstrating efficacy exacerbates this problem – an act of certain risk yielding uncertain
benefit may be frank recklessness.
G6PD deficiency is the most prevalent genetic abnormality of humanity, and it is the most
diverse [16]. Mutations resulting in impaired enzyme activity occur all along the length of
that relatively large gene (approx. 20 kilobases of 13 exons and 12 introns; encoding 515
amino acids). Many dozens of clinically significant G6PDd variants occur, but primaquine
sensitivity phenotype is known in only three: African A- (mild); Mahidol (moderate); and
Mediterranean B- (severe). Stark differences in primaquine sensitivity between A- and B-
variants emphasize the risks imposed with implementation of dosing strategies intended for
use by the US Army. Among A- patients, primaquine hemolyzes older but not younger red
blood cells. One A- G6PDd subject recovered and maintained normal red blood cell counts
despite continuous daily dosing (30mg) for 4 months [6]. In contrast, B- subjects given a
single 45mg dose typically hemolyzed 25% of their red blood cells, and even reticulocytes
remain exquisitely sensitive to subsequent primaquine dosing [17-19]. G6PDd variants
occur in the real world that may seriously threaten patients exposed to primaquine therapies
safely administered to otherwise healthy African-American men. The real world also
includes vulnerable small children, pregnant women, and patients with acute malaria – no
regimen of primaquine has been systematically evaluated for safety in these groups. Experts
have long acknowledged this very significant problem [20], but no research agenda
progressed to redress it.
Beyond the very modest demonstrations of safety and efficacy of the US Army primaquine
regimens in African-American men, the community of science has yet to optimize
primaquine therapies in far broader human populations. Less threatening doses and dosing
regimens adjusted to use with contemporary antimalarials requires specific explorations of
such. Recognizing this avenue of investigation as effectively unexplored begins a process of
reinvention for primaquine therapies.
Reinventing Primaquine
The view of primaquine as dangerous and ineffective must be tempered with understanding
of the failure to fully develop its potential usefulness. The drug, as developed by the US
Army a lifetime ago, left critical avenues of investigation unexplored. Those gaps, relatively
unimportant to soldiers and travelers, are vitally important to chemotherapy of patients in
endemic settings. The community of science should undertake what amounts to full
development of primaquine with strategy focused sharply upon reducing the risk of harm in
G6PDd patients by demonstrating good efficacy at the lowest possible exposure to drug by
fully leveraging co-drug synergism against the parasite.
Arresting transmission
The gametocytocidal dose of 45mg primaquine against P. falciparum was not the minimally
effective dose. The Army sought confirmation that this dose, already in use for
chemoprophylaxis in American soldiers in Vietnam, indeed prevented transmission. The
data leading to the recommendation for a single 45mg dose of primaquine against
transmission of P. falciparum came from just two studies and a total of 14 volunteers [10,
21]. A reporting of findings in another 17 volunteers given 15mg to 45mg primaquine
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therapy was published in an obscure special issue of the journal Military Medicine [22].
Table 2 summarizes those essential findings. Remarkably, a 30mg single dose did almost as
well as the 45mg dose in preventing oocyst formation in mosquitoes, as did a single 15mg
dose. Similarly, although Burgess & Bray [21] firmly recommended the 45mg single dose,
their data also shows 15mg or 30mg being as effective. None of these subjects (except two
controls [22]) received blood schizontocidal co-therapy – the effects of any possible synergy
from therapy of the acute attack are wholly absent. In this retrospect, the decision on anti-
transmission therapy for falciparum malaria seems to have unnecessarily settled upon a
relatively threatening dose. Optimizing gametocytocidal primaquine therapy in patients also
receiving standard artemisinin-combined therapies (ACTs, which indeed kill immature
gametocytes), both in terms of dose and timing, seems highly likely to yield a far less
threatening therapy for G6PDd patients.
Arresting relapse
Primaquine as hypnozoitocide against P. vivax offers several avenues of potential
improvements to safety. The activity of 8-aminoquinolines against hypnozoites is synergized
by at least several co-drugs representing as many chemical families [23]. The phenomenon,
recognized late in the clinical development of primaquine [24], was not exploited, i.e., by
seeking out a partner drug that provided the lowest possible effective dose of primaquine. At
that time chloroquine was already the primary therapy against acute P. vivax malaria. The
chloroquine-primaquine pair provided adequate efficacy against relapse (albeit inferior to
quinine-primaquine [24]), and this radical cure became the last chemotherapeutic innovation
for vivax malaria for over sixty years.
During the 1980s the US Army explored options to primaquine for radical cure, and at least
one investigator revisited the issue of co-drug synergy as a means of delivering less
threatening doses [25]. However, the Army later abandoned radical cure, instead committing
the best 8-aminoquinoline candidate (tafenoquine) to development as a chemoprophylactic
[26]. Co-drug synergy against hypnozoites thus became irrelevant. Around 2004, however,
the Army abandoned tafenoquine for prophylaxis after a very high rate (93%) of vortex
keratopathy occurred among Australian soldiers taking the drug weekly for six months [27].
In 2008 the drug returned to clinical development for radical cure, this time by MMV and
GlaxoSmithKline with the cooperation of the Army. In experiments not designed to detect
the phenomenon, US Army researchers noted the minimally effective dose of tafenoquine
decreased 10-fold when used with blood schizontocide against relapse in the Plasmodium
cynomolgi model [28]. The reinvention of primaquine (and further development of
tafenoquine) should include a deliberate search for co-drugs that provide maximal synergy
against relapse and thus minimal dose and threat of hemolysis.
Arresting hemolysis
Another avenue may be considered in reinventing primaquine. During 1948 the developers
of primaquine working at Stateville Penitentiary in Illinois conducted a series of
experiments in a single prisoner volunteer that did not later appear in peer-reviewed
literature (unlike much of their work). The findings, if verified, promise solution of the
onerous primaquine-G6PDd problem. The experiments were described in a semi-annual
report to US NIH sponsors of the development program [29]. A 60mg daily dose of
pentaquine (a candidate 8-aminoquinoline) caused one subject to have, “…developed severe
acute hemolytic anemia after several days of treatment…” He later suffered the same
outcome with a 30mg daily dose of pamaquine. However, when treated again with a 60mg
daily dose of pentaquine but with 500mg methylene blue daily, he was able to consume that
dose “…for fourteen days without the development of intravascular hemolysis.” The same
report presents data demonstrating methylene blue synergy of the anti-relapse activity of
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isopentaquine (another candidate drug) in Chesson P. vivax (Table 3). Further work on
methylene blue has not yet been discovered in the archives of these studies obtained from
the National Library of Medicine and the Archives of the National Science Foundation. The
reinvention of primaquine should include trials of methylene blue as an adjunct for arrest of
8-aminoquinoline hemolytic toxicity in G6PDd patients.
Reinvented Drug for Reinvented Strategy
Reinvented primaquine would create opportunities for chemotherapeutic strategies aimed at
the entrenched endemic malarias. Gametocytemia silently sowing infectious anopheline
mosquitoes and transmission may be directly attacked on larger and far more aggressive
scales. The stubborn and prevalent hypnozoite reservoir would finally be exposed to safe
and sustained chemotherapeutic assault. Reinvented primaquine may also bring an end to
inefficient and impractical species-specific treatment where both important species occur
together – an ACT and primaquine against transmission and relapse (simultaneously) would
provide radical cure without regard to diagnostic availability or sensitivity.
Primaquine was never developed for use in endemic zones. Its development left critical gaps
in safety that rendered it ineffective or hazardous where most malaria occurs. Exploring and
leveraging co-drug synergies against both transmission and relapse in order to minimize risk
of harm to G6PDd patients can reinvent this vital drug. Despite 60 years of continuous use
as the only treatment against malaria transmission and relapse, primaquine is an emerging
drug in need of a wide range of development work in laboratory, clinical, and endemic
settings.
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Table 3
Methylene blue synergized isopentaquine efficacy against relapse by Chesson strain P. vivax in American
prisoner volunteers.
Methylene blue* Isopentaquine‡ Quinine§ Relapsed/Challenged (%) Followup Duration
0 60 0 9/10 (90%) < 195 d
0 60 2,000 4/10 (40%) 167 – 374 d
500 60 0 3/9 (33%) 123 – 289 d
500 60 2,000 0/3 (0%) 249 d
Adapted from unpublished data of Alving et al. [29]
*
Milligrams of base & chloride salt of methylene blue, daily dose for 14 days.
‡
Milligrams of base daily for 14 days
§
Millgrams of the sulfate salt of quinine
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